The efficacy of immunotherapy with CTLA-4 inhibitors in soft-tissue sarcoma has only been evaluated in one study to-date, in which six patients with synovial sarcoma were treated with ipilimumab (48). This evidence concerns the gene CTLA4 and soft tissue sarcoma.